Grace Therapeutics, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Grace Therapeutics, Inc. (GRCE) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$1.99 million for the 6-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2023-11-13
- Grace Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2023-09-30 was -$537.00K, a 158.12% decline year-over-year.
- Grace Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2023-06-30 was -$1.45M, a 72550.00% decline year-over-year.
- Grace Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2023-03-31 was -$889.00K, a 117.81% decline year-over-year.
- Grace Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2022-12-31 was -$448.00K.
- Grace Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was -$411.00K, a 117.21% decline from fiscal 2022.
- Grace Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $2.39M, a 64.36% decline from fiscal 2021.
- Grace Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2021 was $6.70M.
- Grace Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2020 was -$3.39M, a 145.53% decline from fiscal 2019.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|
| 2023-09-30 | -$537.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-13 | -$1.99M 10-Q · filed 2023-11-13 | -$2.88M derived: sum of 3 quarters · filed 2023-11-13 | -$3.32M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2023-06-30 | -$1.45M 10-Q · filed 2023-08-11 | -$2.34M derived: sum of 2 quarters · filed 2023-08-11 | -$2.79M derived: sum of 3 quarters · filed 2023-08-11 | -$1.86M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2023-03-31 | -$889.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-23 | -$1.34M derived: sum of 2 quarters · filed 2023-06-23 | -$413.00K derived: sum of 3 quarters · filed 2023-11-13 | -$411.00K 10-K · filed 2023-06-23 | |
| 2022-12-31 | -$448.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-14 | $476.00K derived: sum of 2 quarters · filed 2023-11-13 | $478.00K 10-Q · filed 2023-02-14 | $5.47M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-09-30 | $924.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-13 | $926.00K 10-Q · filed 2023-11-13 | $5.92M derived: sum of 3 quarters · filed 2023-11-13 | $4.32M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | $2.00K 10-Q · filed 2023-08-11 | $4.99M derived: sum of 2 quarters · filed 2023-08-11 | $3.40M derived: sum of 3 quarters · filed 2023-08-11 | $2.36M derived: sum of 4 quarters · filed 2023-08-11 | |
| 2022-03-31 | $4.99M derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-23 | $3.40M derived: sum of 2 quarters · filed 2023-06-23 | $2.36M derived: sum of 3 quarters · filed 2023-06-23 | $2.39M 10-K · filed 2023-06-23 | |
| 2021-12-31 | -$1.59M 10-Q · filed 2022-02-14 | -$2.63M derived: sum of 2 quarters · filed 2022-02-14 | -$2.60M 10-Q · filed 2023-02-14 | $9.99M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-09-30 | -$1.04M 10-Q · filed 2021-11-10 | -$1.01M 10-Q · filed 2022-11-14 | $11.58M derived: sum of 3 quarters · filed 2022-08-11 | $9.58M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-06-30 | $27.00K 10-Q · filed 2022-08-11 | $12.62M derived: sum of 2 quarters · filed 2022-08-11 | $10.62M derived: sum of 3 quarters · filed 2022-08-11 | $8.27M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $12.59M derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-21 | $10.59M derived: sum of 2 quarters · filed 2022-06-21 | $8.24M derived: sum of 3 quarters · filed 2022-06-21 | $6.70M 10-K · filed 2022-06-21 | -$6.70M 10-K · filed 2021-06-22 |
| 2020-12-31 | -$2.00M 10-Q · filed 2022-02-14 | -$4.35M derived: sum of 2 quarters · filed 2022-02-14 | -$5.89M 10-Q · filed 2022-02-14 | -$6.94M derived: sum of 4 quarters · filed 2022-02-14 | |
| 2020-09-30 | -$2.35M 10-Q · filed 2021-11-10 | -$3.89M 10-Q · filed 2021-11-10 | -$4.94M derived: sum of 3 quarters · filed 2021-11-10 | -$5.63M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | -$1.54M 10-Q · filed 2021-08-12 | -$2.59M derived: sum of 2 quarters · filed 2021-08-12 | -$3.29M derived: sum of 3 quarters · filed 2021-08-12 | -$5.13M derived: sum of 4 quarters · filed 2021-08-12 | |
| 2020-03-31 | -$1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2021-06-22 | -$1.74M derived: sum of 2 quarters · filed 2021-06-22 | -$3.58M derived: sum of 3 quarters · filed 2021-06-22 | -$3.39M 10-K · filed 2021-06-22 | |
| 2019-12-31 | -$696.00K 10-Q · filed 2021-02-09 | -$2.54M derived: sum of 2 quarters · filed 2021-02-09 | -$2.34M 10-Q · filed 2021-02-09 | ||
| 2019-09-30 | -$1.84M 10-Q · filed 2020-11-16 | -$1.65M 10-Q · filed 2020-11-16 | |||
| 2019-06-30 | $122.00K 10-Q · filed 2020-08-13 | ||||
| 2019-03-31 | $7.44M 10-K · filed 2020-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |